Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST003036)

HILIC NEGATIVE ION MODE (Analysis AN004978)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13	F14	F15	F16	F17	F18	F19	F20	F21	F22
1-4-b-D-Mannan	ME784353	0.85	0.72	0.90	0.93	0.95	0.89	0.84	0.78	0.80	0.87	0.78	0.81	0.92	0.79	0.94	0.90	1.01	1.13	1.05	1.05	1.02	1.86
2^,3^-Cyclic UMP	ME784360	1.02	1.09	0.93	1.02	1.02	0.99	0.96	0.94	1.02	0.94	0.96	0.97	1.08	0.93	0.90	0.94	1.08	1.09	0.94	0.92	0.96	1.02
1-(5^-Phosphoribosyl)-5-amino-4-(N-succinocarboxamide)-imidazole	ME784348	0.68	0.74	0.73	0.56	0.80	0.55	0.86	1.70	1.42	1.20	1.31	1.46	1.31	1.60	NA	NA	NA	NA	NA	NA	NA	0.60
2,3,6-Trihydroxypyridine	ME784305	0.97	0.96	1.81	1.09	1.28	1.21	0.90	1.12	1.10	1.83	0.94	0.73	1.17	0.99	1.28	1.17	1.01	1.18	1.03	1.02	1.25	1.17
2^,3^-Cyclic CMP	ME784359	0.96	1.11	0.82	0.91	0.97	0.96	1.00	0.95	1.06	1.04	0.96	0.96	1.01	1.14	0.98	0.90	1.12	1.02	0.89	1.01	0.96	0.99
1H-Imidazole-4-ethanamine	ME784356	0.88	0.65	1.10	1.04	1.09	1.15	0.90	0.91	0.74	0.91	0.95	0.84	0.94	0.83	1.36	1.32	1.26	1.27	1.30	1.21	1.28	1.12
1-(p-butylphenyl)-2,2-dimethyl-4,6-diamino-1,2-dihydro-s-triazine	ME784350	0.80	0.79	1.04	1.08	1.05	0.99	0.96	0.79	1.20	1.29	1.29	1.19	1.16	0.74	0.81	0.69	0.88	1.01	0.86	0.92	0.93	0.95
1-(beta-D-Ribofuranosyl)-1,4-dihydronicotinamide	ME784349	0.99	0.96	0.84	0.82	0.92	1.03	0.94	0.98	0.90	0.87	0.94	0.93	0.97	0.93	1.40	1.41	1.04	1.11	1.11	1.01	1.34	1.06
2^,3^-Cyclic AMP	ME784358	0.95	0.91	0.89	0.85	0.80	1.00	1.01	1.03	1.08	0.93	0.89	0.86	1.11	1.06	0.90	0.78	1.19	1.17	0.95	1.00	1.05	0.96
11-beta-hydroxyandrosterone-3-glucuronide	ME784352	NA	NA	1.52	1.45	1.35	1.22	0.58	0.49	NA	1.50	1.68	1.43	1.07	0.62	NA	NA	0.81	0.72	0.66	0.94	0.47	0.86
2,3,4,5-Tetrahydrodipicolinate	ME784272	1.54	1.54	0.98	0.97	1.11	1.09	1.42	1.19	1.36	0.99	0.74	0.82	0.95	1.26	1.32	1.46	1.16	1.21	1.10	0.97	1.16	1.16
1,6-anhydro-N-acetylmuramate	ME784282	0.95	0.95	1.25	1.29	1.33	1.11	1.00	0.93	1.01	1.25	1.31	1.25	1.19	0.95	1.19	1.10	1.04	1.06	1.08	1.14	1.19	1.08
15S-hydroxy,14R-(S-cysteinyl)-5Z,8Z,10E,12E-eicosatetraenoic acid	ME784355	0.64	0.65	0.77	0.89	0.68	0.89	0.86	1.03	0.90	1.13	1.36	1.14	1.27	1.00	0.81	0.80	1.06	1.39	0.73	1.01	0.98	1.01
1-Aminocyclopropane-1-carboxylate	ME784294	0.88	0.75	1.07	0.81	0.93	1.08	0.91	0.90	0.86	0.94	0.84	0.87	0.81	0.81	1.87	1.65	1.44	1.60	1.31	1.27	1.65	1.14
2-[3-Ethyl-5-(4-methoxyphenyl)-1H-pyrazol-4-yl]phenol	ME784362	0.98	0.83	1.14	1.11	1.24	1.01	0.85	0.97	1.00	1.04	0.88	0.99	0.95	1.02	0.89	0.83	1.11	0.99	0.89	1.12	0.90	1.04
2,4-diacetamido-2,4,6-trideoxy-beta-L-altropyranose	ME784314	1.04	1.06	1.07	1.05	1.11	1.11	1.16	0.92	1.09	1.01	1.01	1.06	1.09	1.04	1.12	1.16	1.03	1.09	1.06	1.11	1.11	1.07
2,5-Dioxopentanoate	ME784222	0.71	0.55	1.25	1.38	1.13	1.50	0.77	0.85	0.64	1.32	1.48	1.34	1.31	1.00	0.59	0.62	1.12	1.20	0.84	1.22	0.85	1.06
1,4-Bis(2-ethylhexyl) sulfosuccinate	ME784351	0.50	0.68	0.23	0.27	0.20	0.54	13.11	1.88	1.75	0.31	0.53	0.19	0.25	0.52	0.79	0.98	0.18	0.26	0.29	0.17	0.45	0.57
15-Keto-prostaglandinE2	ME784354	0.72	0.89	0.49	0.38	0.72	0.45	0.60	0.69	0.80	0.63	0.47	1.46	0.47	0.68	0.77	1.18	0.47	0.74	0.47	0.44	0.40	0.67

Factors:

F1	treatment:M_Cefto_3g_143h
F2	treatment:M_Cefto_3g_167h
F3	treatment:M_Cefto_3g_23h
F4	treatment:M_Cefto_3g_47h
F5	treatment:M_Cefto_3g_71h
F6	treatment:M_Cefto_3g_7h
F7	treatment:M_Cefto_3g_95h
F8	treatment:M_Cefto_6g_143h
F9	treatment:M_Cefto_6g_167h
F10	treatment:M_Cefto_6g_23h
F11	treatment:M_Cefto_6g_47h
F12	treatment:M_Cefto_6g_71h
F13	treatment:M_Cefto_6g_7h
F14	treatment:M_Cefto_6g_95h
F15	treatment:M_Control_143h
F16	treatment:M_Control_167h
F17	treatment:M_Control_23h
F18	treatment:M_Control_47h
F19	treatment:M_Control_71h
F20	treatment:M_Control_7h
F21	treatment:M_Control_95h
F22	treatment:Pooled QC

Data matrix